Microbiology and risk factors for community-acquired pneumonia

Seminars in Respiratory and Critical Care Medicine

Volumn 33, Issue 3, 2012, Pages 220-231

  Herrero, Francisco Sanz ^a   Olivas, José Blanquer ^a  

^a UNIVERSITY OF VALENCIA   (Spain)

Author keywords

COPD; influenza; risk factors; Streptococcus pneumoniae; vaccines

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INFLUENZA VACCINE; PNEUMOCOCCUS VACCINE;

AGING; ALCOHOLISM; ARTICLE; CHLAMYDOPHILA PNEUMONIAE; CHRONIC LIVER DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMMUNITY ACQUIRED PNEUMONIA; COMORBIDITY; DIABETES MELLITUS; DISEASE SEVERITY; ENTEROBACTERIACEAE; ETHNICITY; GROUPS BY AGE; HAEMOPHILUS INFLUENZAE; HOSPITALIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTENSIVE CARE UNIT; KIDNEY FAILURE; LEGIONELLA; MICROBIOLOGICAL EXAMINATION; MIXED INFECTION; MOUTH HYGIENE; MYCOPLASMA PNEUMONIAE; NURSING HOME PATIENT; OUTPATIENT DEPARTMENT; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; SCORING SYSTEM; SEX DIFFERENCE; SMOKING CESSATION; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; VIRUS; VIRUS PNEUMONIA;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; AGE FACTORS; ALCOHOL DRINKING; ANTI-ASTHMATIC AGENTS; COMMUNITY-ACQUIRED INFECTIONS; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; ORTHOMYXOVIRIDAE; PNEUMOCOCCAL VACCINES; PNEUMONIA; PNEUMONIA, PNEUMOCOCCAL; PNEUMONIA, VIRAL; RISK FACTORS; SEX FACTORS; SMOKING; STREPTOCOCCUS PNEUMONIAE;

EID: 84862502029     PISSN: 10693424     EISSN: 10989048     Source Type: Journal    
DOI: 10.1055/s-0032-1315634     Document Type: Article

References (134)

1. Apisarnthanarak A, Mundy LM. Etiology of community-acquired pneumonia. Clin Chest Med: 2005; 26 1 47 55 (Pubitemid 40410702)
2. Jokinen C, Heiskanen L, Juvonen H., et al. Incidence of community-acquired pneumonia in the population of four municipalities in eastern Finland. Am J Epidemiol: 1993; 137 9 977 988 (Pubitemid 23191065)
3. Welte T, Torres A, Nathwani D. Clinical and economic burden of community-acquired pneumonia among adults in Europe. Thorax: 2012; 67 1 71 79
4. Almirall J, Bolíbar I, Vidal J., et al. Epidemiology of community-acquired pneumonia in adults: a population-based study. Eur Respir J: 2000; 15 4 757 763 (Pubitemid 30196306)
5. File TM Jr, Marrie TJ. Burden of community-acquired pneumonia in North American adults. Postgrad Med: 2010; 122 2 130 141
6. World Health Organization World Health Report 2003. Shaping the Future. Geneva World Health Organization: 2003
7. Ewig S, Birkner N, Strauss R., et al. New perspectives on community-acquired pneumonia in 388 406 patients: results from a nationwide mandatory performance measurement programme in healthcare quality. Thorax: 2009; 64 12 1062 1069
8. Lim WS, Baudouin SV, George RC., et al. Pneumonia Guidelines Committee of the BTS Standards of Care Committee. BTS Guidelines for the management of community acquired pneumonia in adults: update 2009. Thorax: 2009; 64 03 iii1 iii55
9. Torres A, Serra-Batlles J, Ferrer A., et al. Severe community-acquired pneumonia. Epidemiology and prognostic factors. Am Rev Respir Dis: 1991; 144 2 312 318
10. Carbonara S, Monno L, Longo B, Angarano G. Community-acquired pneumonia. Curr Opin Pulm Med: 2009; 15 3 261 273
11. Ewig S, Torres A, Angeles Marcos M., et al. Factors associated with unknown aetiology in patients with community-acquired pneumonia. Eur Respir J: 2002; 20 5 1254 1262 (Pubitemid 35331886)
12. Garau J, Baquero F, Pérez-Trallero E., et al. NACER Group. Factors impacting on length of stay and mortality of community-acquired pneumonia. Clin Microbiol Infect: 2008; 14 4 322 329 (Pubitemid 351356522)
13. Charles PG, Whitby M, Fuller AJ., et al. Australian CAP Study Collaboration. The etiology of community-acquired pneumonia in Australia: why penicillin plus doxycycline or a macrolide is the most appropriate therapy. Clin Infect Dis: 2008; 46 10 1513 1521 (Pubitemid 351706731)
14. Mandell L. Treatment of community-acquired pneumonia Down Under versus the United States: is it really that different? Clin Infect Dis: 2008; 46 10 1522 1524 (Pubitemid 351706732)
15. Clark NM, Lynch JP III. Influenza: epidemiology, clinical features, therapy, and prevention. Semin Respir Crit Care Med: 2011; 32 4 373 392
16. Walsh EE. Respiratory syncytial virus infection in adults. Semin Respir Crit Care Med: 2011; 32 4 423 432
17. Lynch JP III, Fishbein M, Echavarria M. Adenovirus. Semin Respir Crit Care Med: 2011; 32 4 494 511
18. Kroll JL, Weinberg A. Human metapneumovirus. Semin Respir Crit Care Med: 2011; 32 4 447 453
19. Greenberg SB. Update on rhinovirus and coronavirus infections. Semin Respir Crit Care Med: 2011; 32 4 433 446
20. Alfageme I, Aspa J, Bello S., et al. Grupo de Estudio de la Neumonía Adquirida en la Comunidad. Area de Tuberculosis e Infecciones Respiratorias (TIR)-SEPAR; Spanish Society of Pulmonology and Thoracic Surgery (SEPAR). [Guidelines for the diagnosis and management of community-acquired pneumonia]. Arch Bronconeumol: 2005; 41 5 272 289
21. Marrie TJ, Bartlett JG, Thorner AR. Epidemiology, pathogenesis, and microbiology of community-acquired pneumonia in adults. UpToDate. http://www.uptodate.com/contents/epidemiology-pathogenesis-and-microbiology-of- community-acquired-pneumonia-in-adults. Accessed September 5, 2011
22. Brown JS. Geography and the aetiology of community-acquired pneumonia. Respirology: 2009; 14 8 1068 1071
23. Woodhead M. The European vision of community-acquired pneumonia. Semin Respir Crit Care Med: 2009; 30 2 136 145
24. Falguera M, Sacristán O, Nogués A., et al. Nonsevere community-acquired pneumonia: correlation between cause and severity or comorbidity. Arch Intern Med: 2001; 161 15 1866 1872 (Pubitemid 32762733)
25. Ruiz-González A, Falguera M, Nogués A, Rubio-Caballero M. Is Streptococcus pneumoniae the leading cause of pneumonia of unknown etiology? A microbiologic study of lung aspirates in consecutive patients with community-acquired pneumonia. Am J Med: 1999; 106 4 385 390 (Pubitemid 29190589)
26. Westall GP, Paraskeva M. H1N1 influenza: critical care aspects. Semin Respir Crit Care Med: 2011; 32 4 400 408
27. Bulpa P, Dive A, Sibille Y. Invasive pulmonary aspergillosis in patients with chronic obstructive pulmonary disease. Eur Respir J: 2007; 30 4 782 800 (Pubitemid 351194841)
28. Kaplan JE, Hanson D, Dworkin MS., et al. Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy. Clin Infect Dis: 2000; 30 01 S5 S14
29. Nyamande K, Lalloo UG, John M. TB presenting as community-acquired pneumonia in a setting of high TB incidence and high HIV prevalence. Int J Tuberc Lung Dis: 2007; 11 12 1308 1313
30. Liam CK, Pang YK, Poosparajah S. Pulmonary tuberculosis presenting as community-acquired pneumonia. Respirology: 2006; 11 6 786 792 (Pubitemid 44581445)
31. Song JH, Oh WS, Kang CI., et al. Asian Network for Surveillance of Resistant Pathogens Study Group. Epidemiology and clinical outcomes of community-acquired pneumonia in adult patients in Asian countries: a prospective study by the Asian network for surveillance of resistant pathogens. Int J Antimicrob Agents: 2008; 31 2 107 114
32. Boonsawat W, Boonma P, Tangdajahiran T, Paupermpoonsiri S, Wongpratoom W, Romphryk A. Community-acquired pneumonia in adults at Srinagarind Hospital. J Med Assoc Thai: 1990; 73 6 345 352
33. Hui KP, Chin NK, Chow K., et al. Prospective study of the aetiology of adult community acquired bacterial pneumonia needing hospitalisation in Singapore. Singapore Med J: 1993; 34 4 329 334
34. Cillóniz C, Ewig S, Polverino E., et al. Microbial aetiology of community-acquired pneumonia and its relation to severity. Thorax: 2011; 66 4 340 346
35. Rosón B, Carratalá J, Dorca J, Casanova A, Manresa F, Gudiol F. Etiology, reasons for Hospitalization, Risk Classes, and Outcomes of Community-Acquired Pneumonia in Patients Hospitalized on the Basis Of Conventional Admission Criteria. Clin Infect Dis: 2001; 33 2 158 165 (Pubitemid 32643329)
36. Dambrava PG, Torres A, Vallès X., et al. Adherence to guidelines' empirical antibiotic recommendations and community-acquired pneumonia outcome. Eur Respir J: 2008; 32 4 892 901
37. Lynch JP III, Zhanel GG. Streptococcus pneumoniae: epidemiology, risk factors, and strategies for prevention. Semin Respir Crit Care Med: 2009; 30 2 189 209
38. Briones ML, Blanquer J, Ferrando D, Blasco ML, Gimeno C, Marín J. Assessment of analysis of urinary pneumococcal antigen by immunochromatography for etiologic diagnosis of community-acquired pneumonia in adults. Clin Vaccine Immunol: 2006; 13 10 1092 1097 (Pubitemid 44622535)
39. Ruuskanen O, Lahti E, Jennings LC, Murdoch DR. Viral pneumonia. Lancet: 2011; 377 9773 1264 1275
40. Lieberman D, Shimoni A, Shemer-Avni Y, Keren-Naos A, Shtainberg R, Lieberman D. Respiratory viruses in adults with community-acquired pneumonia. Chest: 2010; 138 4 811 816
41. Niederman MS. Viral community-acquired pneumonia: if we do not diagnose it and do not treat it, can it still hurt us? Chest: 2010; 138 4 767 769
42. Christian MD, Poutanen SM, Loutfy MR, Muller MP, Low DE. Severe acute respiratory syndrome. Clin Infect Dis: 2004; 38 10 1420 1427 (Pubitemid 38668590)
43. World Health Organization Cumulative Number of Confirmed Human Cases of Avian Influenza A/(H5N1). Reported to WHO. http://www.who.int/csr/disease/avian- influenza/country/cases-table-2010-08-31/en/index.html. Accessed September 5, 2011
44. de Roux A, Ewig S, García E., et al. Mixed community-acquired pneumonia in hospitalised patients. Eur Respir J: 2006; 27 4 795 800 (Pubitemid 44914205)
45. Torres A, Dorca J, Zalacaín R., et al. Community-acquired pneumonia in chronic obstructive pulmonary disease: a Spanish multicenter study. Am J Respir Crit Care Med: 1996; 154 5 1456 1461 (Pubitemid 26391197)
46. Restrepo MI, Mortensen EM, Pugh JA, Anzueto A. COPD is associated with increased mortality in patients with community-acquired pneumonia. Eur Respir J: 2006; 28 2 346 351 (Pubitemid 44914234)
47. Sanz F, Blanquer J. Community-acquired pneumonia in chronic obstructive pulmonary disease patients. Minerva pneumol: 2009; 48 85 94
48. Fernández-Sabé N, Carratalà J, Rosón B., et al. Community-acquired pneumonia in very elderly patients: causative organisms, clinical characteristics, and outcomes. Medicine (Baltimore): 2003; 82 3 159 169 (Pubitemid 36578705)
49. de Roux A, Cavalcanti M, Marcos MA., et al. Impact of alcohol abuse in the etiology and severity of community-acquired pneumonia. Chest: 2006; 129 5 1219 1225
50. Osler W. The Principles and Practice of Medicine. New York D Appleton: 1901
51. Ewig S, Birkner N, Strauss R., et al. New perspectives on community-acquired pneumonia in 388 406 patients. Results from a nationwide mandatory performance measurement programme in healthcare quality. Thorax: 2009; 64 12 1062 1069
52. Butler SG, Stuart A, Leng X, Rees C, Williamson J, Kritchevsky SB. Factors influencing aspiration during swallowing in healthy older adults. Laryngoscope: 2010; 120 11 2147 2152
53. Ho JC, Chan KN, Hu WH., et al. The effect of aging on nasal mucociliary clearance, beat frequency, and ultrastructure of respiratory cilia. Am J Respir Crit Care Med: 2001; 163 4 983 988 (Pubitemid 32275875)
54. Riquelme R, Torres A, El-Ebiary M., et al. Community-acquired pneumonia in the elderly: A multivariate analysis of risk and prognostic factors. Am J Respir Crit Care Med: 1996; 154 5 1450 1455 (Pubitemid 26391196)
55. Franceschi C, Bonafè M, Valensin S. Human immunosenescence: the prevailing of innate immunity, the failing of clonotypic immunity, and the filling of immunological space. Vaccine: 2000; 18 16 1717 1720 (Pubitemid 30109535)
56. Plowden J, Renshaw-Hoelscher M, Engleman C, Katz J, Sambhara S. Innate immunity in aging: impact on macrophage function. Aging Cell: 2004; 3 4 161 167 (Pubitemid 40246681)
57. Kaplan V, Angus DC, Griffin MF, Clermont G, Scott Watson R, Linde-Zwirble WT. Hospitalized community-acquired pneumonia in the elderly: age- and sex-related patterns of care and outcome in the United States. Am J Respir Crit Care Med: 2002; 165 6 766 772 (Pubitemid 34229645)
58. Schröder J, Kahlke V, Book M, Stüber F. Gender differences in sepsis: genetically determined? Shock: 2000; 14 3 307 310, discussion 310-313
59. Frei CR, Mortensen EM, Copeland LA., et al. Disparities of care for African-Americans and Caucasians with community-acquired pneumonia: a retrospective cohort study. BMC Health Serv Res: 2010; 10 143
60. Restrepo MI, Velez MI, Serna G, Anzueto A, Mortensen EM. Antimicrobial resistance in Hispanic patients hospitalized in San Antonio, TX with community-acquired pneumonia. Hosp Pract (Minneap): 2010; 38 4 108 113
61. Janssens JP, Krause KH. Pneumonia in the very old. Lancet Infect Dis: 2004; 4 2 112 124
62. Mehr DR, Zweig SC, Kruse RL., et al. Mortality from lower respiratory infection in nursing home residents. A pilot prospective community-based study. J Fam Pract: 1998; 47 4 298 304 (Pubitemid 28491476)
63. El-Solh AA, Sikka P, Ramadan F, Davies J. Etiology of severe pneumonia in the very elderly. Am J Respir Crit Care Med: 2001; 163 3 Pt 1 645 651 (Pubitemid 32230823)
64. Naimi TS, LeDell KH, Como-Sabetti K., et al. Comparison of community- and health care-associated methicillin-resistant Staphylococcus aureus infection. JAMA: 2003; 290 22 2976 2984 (Pubitemid 37505530)
65. American Thoracic Society; Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med: 2005; 171 4 388 416
66. Nuorti JP, Butler JC, Farley MM., et al. Active Bacterial Core Surveillance Team. Cigarette smoking and invasive pneumococcal disease. N Engl J Med: 2000; 342 10 681 689 (Pubitemid 30131420)
67. Centers for Disease Control and Prevention (CDC). Cigarette smoking-attributable mortality and years of potential life lostUnited States, 1990. MMWR Morb Mortal Wkly Rep: 1993; 42 33 645 649
68. Almirall J, González CA, Balanzó X, Bolíbar I. Proportion of community-acquired pneumonia cases attributable to tobacco smoking. Chest: 1999; 116 2 375 379 (Pubitemid 29382121)
69. Ewig S, Ruiz M, Torres A., et al. Pneumonia acquired in the community through drug-resistant Streptococcus pneumoniae. Am J Respir Crit Care Med: 1999; 159 6 1835 1842 (Pubitemid 29275052)
70. Fernández-Solá J, Junqué A, Estruch R, Monforte R, Torres A, Urbano-Márquez A. High alcohol intake as a risk and prognostic factor for community-acquired pneumonia. Arch Intern Med: 1995; 155 15 1649 1654
71. Samokhvalov AV, Irving HM, Rehm J. Alcohol consumption as a risk factor for pneumonia: a systematic review and meta-analysis. Epidemiol Infect: 2010; 138 12 1789 1795
72. Happel KI, Nelson S. Alcohol, immunosuppression, and the lung. Proc Am Thorac Soc: 2005; 2 5 428 432 (Pubitemid 43128038)
73. Raasch CE, Zhang P, Siggins RW II, LaMotte LR, Nelson S, Bagby GJ. Acute alcohol intoxication impairs the hematopoietic precursor cell response to pneumococcal pneumonia. Alcohol Clin Exp Res: 2010; 34 12 2035 2043
74. Almirall J, Bolíbar I, Serra-Prat M., et al. Community-Acquired Pneumonia in Catalan Countries (PACAP) Study Group. New evidence of risk factors for community-acquired pneumonia: a population-based study. Eur Respir J: 2008; 31 6 1274 1284
75. El-Solh AA, Pietrantoni C, Bhat A., et al. Colonization of dental plaques: a reservoir of respiratory pathogens for hospital-acquired pneumonia in institutionalized elders. Chest: 2004; 126 5 1575 1582 (Pubitemid 39525034)
76. Paju S, Scannapieco FA. Oral biofilms, periodontitis, and pulmonary infections. Oral Dis: 2007; 13 6 508 512 (Pubitemid 47609899)
77. Chatila WM, Thomashow BM, Minai OA, Criner GJ, Make BJ. Comorbidities in chronic obstructive pulmonary disease. Proc Am Thorac Soc: 2008; 5 4 549 555 (Pubitemid 351669185)
78. Lange P, Vestbo J, Nyboe J. Risk factors for death and hospitalization from pneumonia. A prospective study of a general population. Eur Respir J: 1995; 8 10 1694 1698
79. Sliedrecht A, den Elzen WP, Verheij TJ, Westendorp RG, Gussekloo J. Incidence and predictive factors of lower respiratory tract infections among the very elderly in the general population. The Leiden 85-plus Study. Thorax: 2008; 63 9 817 822
80. Jansen HM, Sachs AP, van Alphen L. Predisposing conditions to bacterial infections in chronic obstructive pulmonary disease. Am J Respir Crit Care Med: 1995; 151 6 2073 2080
81. Marin A, Monsó E, Garcia-Nuñez M., et al. Variability and effects of bronchial colonisation in patients with moderate COPD. Eur Respir J: 2010; 35 2 295 302
82. Sethi S, Murphy TF. Infection in the pathogenesis and course of chronic obstructive pulmonary disease. N Engl J Med: 2008; 359 22 2355 2365
83. Gutierrez P, Closa D, Piñer R, Bulbena O, Menéndez R, Torres A. Macrophage activation in exacerbated COPD with and without community-acquired pneumonia. Eur Respir J: 2010; 36 2 285 291
84. File TM Jr, Monte SV, Schentag JJ., et al. A disease model descriptive of progression between chronic obstructive pulmonary disease exacerbations and community-acquired pneumonia: roles for underlying lung disease and the pharmacokinetics/pharmacodynamics of the antibiotic. Int J Antimicrob Agents: 2009; 33 1 58 64
85. Rabe KF, Hurd S, Anzueto A., et al. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med: 2007; 176 6 532 555 (Pubitemid 47403272)
86. Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, Maslen TK. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ: 2000; 320 7245 1297 1303 (Pubitemid 30245717)
87. Calverley PM, Anderson JA, Celli B., et al. TORCH investigators. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med: 2007; 356 8 775 789 (Pubitemid 46294610)
88. Ernst P, Gonzalez AV, Brassard P, Suissa S. Inhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumonia. Am J Respir Crit Care Med: 2007; 176 2 162 166 (Pubitemid 47057852)
89. Calverley PM, Stockley RA, Seemungal TA., et al. Investigating New Standards for Prophylaxis in Reduction of Exacerbations (INSPIRE) Investigators. Reported pneumonia in patients with COPD: findings from the INSPIRE study. Chest: 2011; 139 3 505 512
90. Wilson AM, Lipworth BJ. Systemic dose-response relationships with oral and inhaled corticosteroids in asthmatics [abstract]. Thorax: 1997; 52 06 A57 (Pubitemid 127813069)
91. Lipworth BJ. Systemic adverse effects of inhaled corticosteroid therapy: a systematic review and meta-analysis. Arch Intern Med: 1999; 159 9 941 955 (Pubitemid 29222495)
92. White DA. Drug-induced pulmonary infection. Clin Chest Med: 2004; 25 1 179 187 (Pubitemid 38296342)
93. Shah BR, Hux JE. Quantifying the risk of infectious diseases for people with diabetes. Diabetes Care: 2003; 26 2 510 513 (Pubitemid 36929083)
94. Muller LM, Gorter KJ, Hak E., et al. Increased risk of common infections in patients with type 1 and type 2 diabetes mellitus. Clin Infect Dis: 2005; 41 3 281 288 (Pubitemid 41022101)
95. Thomsen RW, Hundborg HH, Lervang HH, Johnsen SP, Schonheyder HC, Sorensen HT. Risk of community-acquired pneumococcal bacteremia in patients with diabetes: a population-based case-control study. Diabetes Care: 2004; 27 5 1143 1147 (Pubitemid 38579780)
96. Kornum JB, Thomsen RW, Riis A, Lervang HH, Schonheyder HC, Sorensen HT. Diabetes, glycemic control, and risk of hospitalization with pneumonia: a population-based case-control study. Diabetes Care: 2008; 31 8 1541 1545
97. Koziel H, Koziel MJ. Pulmonary complications of diabetes mellitus. Pneumonia. Infect Dis Clin North Am: 1995; 9 1 65 96
98. Naqvi SB, Collins AJ. Infectious complications in chronic kidney disease. Adv Chronic Kidney Dis: 2006; 13 3 199 204 (Pubitemid 43947730)
99. Slinin Y, Foley RN, Collins AJ. Clinical epidemiology of pneumonia in hemodialysis patients: the USRDS waves 1, 3, and 4 study. Kidney Int: 2006; 70 6 1135 1141 (Pubitemid 44344085)
100. James MT, Quan H, Tonelli M., et al. Alberta Kidney Disease Network. CKD and risk of hospitalization and death with pneumonia. Am J Kidney Dis: 2009; 54 1 24 32
101. James MT, Laupland KB, Tonelli M, Manns BJ, Culleton BF, Hemmelgarn BR.; Alberta Kidney Disease Network. Risk of bloodstream infection in patients with chronic kidney disease not treated with dialysis. Arch Intern Med: 2008; 168 21 2333 2339
102. Viasus D, Garcia-Vidal C, Cruzado JM., et al. Epidemiology, clinical features and outcomes of pneumonia in patients with chronic kidney disease. Nephrol Dial Transplant: 2011; 26 9 2899 2906
103. Cendoroglo M, Jaber BL, Balakrishnan VS, Perianayagam M, King AJ, Pereira BJ. Neutrophil apoptosis and dysfunction in uremia. J Am Soc Nephrol: 1999; 10 1 93 100 (Pubitemid 29034947)
104. Foley RN. Infections and cardiovascular disease in patients with chronic kidney disease. Adv Chronic Kidney Dis: 2006; 13 3 205 208 (Pubitemid 43947732)
105. Borzio M, Salerno F, Piantoni L., et al. Bacterial infection in patients with advanced cirrhosis: a multicentre prospective study. Dig Liver Dis: 2001; 33 1 41 48 (Pubitemid 32186174)
106. Tandon P, Garcia-Tsao G. Bacterial infections, sepsis, and multiorgan failure in cirrhosis. Semin Liver Dis: 2008; 28 1 26 42 (Pubitemid 351326531)
107. Viasus D, Garcia-Vidal C, Castellote J., et al. Community-acquired pneumonia in patients with liver cirrhosis: clinical features, outcomes, and usefulness of severity scores. Medicine (Baltimore): 2011; 90 2 110 118
108. Cordero E, Pachón J, Rivero A., et al. Community-acquired bacterial pneumonia in human immunodeficiency virus-infected patients: validation of severity criteria. The Grupo Andaluz para el Estudio de las Enfermedades Infecciosas. Am J Respir Crit Care Med: 2000; 162 6 2063 2068 (Pubitemid 32051665)
109. Navin TR, Rimland D, Lennox JL., et al. Risk factors for community-acquired pneumonia among persons infected with human immunodeficiency virus. J Infect Dis: 2000; 181 1 158 164 (Pubitemid 30049044)
110. Hirschtick RE, Glassroth J, Jordan MC., et al. Pulmonary Complications of HIV Infection Study Group. Bacterial pneumonia in persons infected with the human immunodeficiency virus. N Engl J Med: 1995; 333 13 845 851
111. Klare B, Kubini R, Ewig S. Risk factors for pneumonia in patients with cardiovascular diseases [in German]. Pneumologie: 2002; 56 12 781 788 (Pubitemid 36071822)
112. Fujiki R, Kawayama T, Ueyama T, Ichiki M, Aizawa H. The risk factors for mortality of community-acquired pneumonia in Japan. J Infect Chemother: 2007; 13 3 157 165 (Pubitemid 47012499)
113. Fine MJ, Smith MA, Carson CA., et al. Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis. JAMA: 1996; 275 2 134 141
114. Meijvis SC, Cornips MC, Voorn GP., et al. Microbial evaluation of proton-pump inhibitors and the risk of pneumonia. Eur Respir J: 2011; 38 5 1165 1172
115. Kollef MH, Morrow LE, Baughman RP., et al. Health care-associated pneumonia (HCAP): a critical appraisal to improve identification, management, and outcomesproceedings of the HCAP Summit. Clin Infect Dis: 2008; 46 04 S296 S334, quiz 335-338 (Pubitemid 351590141)
116. Yu VL, Chiou CC, Feldman C., et al. International Pneumococcal Study Group. An international prospective study of pneumococcal bacteremia: correlation with in vitro resistance, antibiotics administered, and clinical outcome. Clin Infect Dis: 2003; 37 2 230 237 (Pubitemid 36930354)
117. Vanderkooi OG, Low DE, Green K, Powis JE, McGeer A.; Toronto Invasive Bacterial Disease Network. Predicting antimicrobial resistance in invasive pneumococcal infections. Clin Infect Dis: 2005; 40 9 1288 1297 (Pubitemid 40570238)
118. González C, Rubio M, Romero-Vivas J, González M, Picazo JJ. Bacteremic pneumonia due to Staphylococcus aureus: a comparison of disease caused by methicillin-resistant and methicillin-susceptible organisms. Clin Infect Dis: 1999; 29 5 1171 1177 (Pubitemid 30265635)
119. El Solh AA, Pietrantoni C, Bhat A, Bhora M, Berbary E. Indicators of potentially drug-resistant bacteria in severe nursing home-acquired pneumonia. Clin Infect Dis: 2004; 39 4 474 480 (Pubitemid 39120921)
120. Arancibia F, Bauer TT, Ewig S., et al. Community-acquired pneumonia due to gram-negative bacteria and pseudomonas aeruginosa: incidence, risk, and prognosis. Arch Intern Med: 2002; 162 16 1849 1858
121. Whitney CG, Farley MM, Hadler J., et al. Active Bacterial Core Surveillance of the Emerging Infections Program Network. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med: 2003; 348 18 1737 1746 (Pubitemid 36514704)
122. Kyaw MH, Lynfield R, Schaffner W., et al. Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae. N Engl J Med: 2006; 354 14 1455 1463
123. Stephens DS, Zughaier SM, Whitney CG., et al. Georgia Emerging Infections Program. Incidence of macrolide resistance in Streptococcus pneumoniae after introduction of the pneumococcal conjugate vaccine: population-based assessment. Lancet: 2005; 365 9462 855 863 (Pubitemid 40332163)
124. Singleton RJ, Hennessy TW, Bulkow LR., et al. Invasive pneumococcal disease caused by nonvaccine serotypes among Alaska Native children with high levels of 7-valent pneumococcal conjugate vaccine coverage. JAMA: 2007; 297 16 1784 1792 (Pubitemid 46658647)
125. Albrich WC, Baughman W, Schmotzer B, Farley MM. Changing characteristics of invasive pneumococcal disease in Metropolitan Atlanta, Georgia, after introduction of a 7-valent pneumococcal conjugate vaccine. Clin Infect Dis: 2007; 44 12 1569 1576 (Pubitemid 46871503)
126. Johnstone J, Eurich DT, Minhas JK, Marrie TJ, Majumdar SR. Impact of the pneumococcal vaccine on long-term morbidity and mortality of adults at high risk for pneumonia. Clin Infect Dis: 2010; 51 1 15 22
127. Use of influenza A (H1N1) 2009 monovalent vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. National Center for Immunization and Respiratory Diseases. CDC (Centers for Disease Control and Prevention). MMWR Morb Mortal Wkly Rep: 2009; 58 RR-10 1 8
128. Chowell G, Bertozzi SM, Colchero MA., et al. Severe respiratory disease concurrent with the circulation of H1N1 influenza. N Engl J Med: 2009; 361 7 674 679
129. Liappis AP, Kan VL, Rochester CG, Simon GL. The effect of statins on mortality in patients with bacteremia. Clin Infect Dis: 2001; 33 8 1352 1357 (Pubitemid 32955186)
130. Mortensen EM, Pugh MJ, Copeland LA., et al. Impact of statins and angiotensin-converting enzyme inhibitors on mortality of subjects hospitalised with pneumonia. Eur Respir J: 2008; 31 3 611 617
131. Ohkubo T, Chapman N, Neal B, Woodward M, Omae T, Chalmers J.; Perindopril Protection Against Recurrent Stroke Sutdy Collaborative Group. Effects of an angiotensin-converting enzyme inhibitor-based regimen on pneumonia risk. Am J Respir Crit Care Med: 2004; 169 9 1041 1045 (Pubitemid 38543644)
132. Siempos II, Vardakas KZ, Kopterides P, Falagas ME. Adjunctive therapies for community-acquired pneumonia: a systematic review. J Antimicrob Chemother: 2008; 62 4 661 668
133. Nuorti JP, Butler JC, Farley MM., et al. Active Bacterial Core Surveillance Team. Cigarette smoking and invasive pneumococcal disease. N Engl J Med: 2000; 342 10 681 689 (Pubitemid 30131420)
134. Tonnesen P, Carrozzi L, Fagerström KO., et al. Smoking cessation in patients with respiratory diseases: a high priority, integral component of therapy. Eur Respir J: 2007; 29 2 390 417 (Pubitemid 46231920)